Scarica l'app Stockscreener
0.52
5.45%
-0.03
Invivyd Inc Borsa (IVVD) Ultime notizie
IVVD Stock Price and Chart — NASDAQ:IVVD - TradingView
Invivyd Appoints Ajay Royan to its Board of Directors - citybiz
Invivyd adds venture capitalist Ajay Royan to board By Investing.com - Investing.com South Africa
Invivyd Appoints Ajay Royan to Board of Directors - TipRanks
Invivyd adds venture capitalist Ajay Royan to board - Investing.com India
Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors - The Manila Times
Major Investor Takes Board Seat: Invivyd Eyes Breakthrough Beyond COVID-19 Treatment - Stock Titan
Invivyd’s (IVVD) Buy Rating Reiterated at D. Boral Capital - Defense World
Invivyd, Inc. (IVVD) Reports Q4 Loss, Tops Revenue Estimates - MSN
INVIVYD SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Invivyd, Inc. – IVVD, ADGI - Business Wire
Invivyd Reports Strong Revenue Growth and Promising Developments - TipRanks
Invivyd earnings beat by $0.08, revenue fell short of estimates - Investing.com Canada
Invivyd, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 -March 20, 2025 at 08:12 am EDT - MarketScreener
Invivyd, Inc. SEC 10-K Report - TradingView
Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights - The Manila Times
Invivyd, Inc. Reports 48% Q4 Revenue Growth for PEMGARDA™ and Advances Next-Generation Antibody VYD2311 - Nasdaq
Invivyd, Inc. Full Year Loss Decreases, But Misses Estimates - Nasdaq
Invivyd (IVVD) Projected to Post Earnings on Thursday - Defense World
Are Investors Undervaluing Invivyd, Inc. (IVVD) Right Now? - Yahoo Finance
D. Boral Capital Reiterates Buy Rating for Invivyd (NASDAQ:IVVD) - MarketBeat
Invivyd reports pemivibart maintains efficacy against SARS-CoV-2 By Investing.com - Investing.com Canada
Invivyd reports pemivibart maintains efficacy against SARS-CoV-2 - Investing.com India
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1 - The Manila Times
Invivyd's COVID Treatment Still Works Against Elusive LP.8.1 VariantCritical News for Immunocompromised Patients - StockTitan
Invivyd (NasdaqGM:IVVD) Jumps 163% After Promising Phase 1/2 Trial Results For COVID-19 Antibody - Simply Wall St
Invivyd Inc [IVVD] Insider Activity: An Update for Investors - Knox Daily
Why Invivyd, Inc. (IVVD) is Skyrocketing So Far in 2025 - Insider Monkey
Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
D. Boral Capital Reiterates “Buy” Rating for Invivyd (NASDAQ:IVVD) - Armenian Reporter
The Zacks Analyst Blog Highlights INVIVYD, 21Vianet, FuboTV, Noodles and Digital Turbine - Yahoo Finance
Invivyd (NASDAQ:IVVD) Receives “Buy” Rating from D. Boral Capital - Defense World
Invivyd (NASDAQ:IVVD) Given “Buy” Rating at HC Wainwright - Defense World
FDA declines Invivyd's COVID-19 treatment EUA expansion By Investing.com - Investing.com Australia
FDA declines Invivyd’s COVID-19 treatment EUA expansion By Investing.com - Investing.com Nigeria
IVVD Stock: More Upside For Invivyd Inc (NASDAQ: IVVD)? - Marketing Sentinel
FDA Rejects Invivyd's Request To Expand Emergency Authorization For Preventive COVID-19 Antibody For Immunocompromised Patients - Benzinga
Sector Update: Health Care Stocks Flat to Higher Pre-Bell Monday - TradingView
Invivyd says FDA declines request to expand existing EUA of PEMGARDA - TipRanks
Sector Update: Health Care - TradingView
5 Stocks That More Than Doubled Halfway Through Q1 - Zacks Investment Research
Invivyd's Request to Treat Covid-19 Patients With Pemgarda Rejected by US FDA -February 24, 2025 at 08:04 am EST - Marketscreener.com
Invivyd shares drop as FDA declines company's COVID-19 treatment EUA expansion - MSN
FDA declines Invivyd’s COVID-19 treatment EUA expansion - Investing.com India
FDA Declined Invivyd's Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Chang - The Manila Times
Can PEMGARDA Still Succeed? FDA Blocks COVID Treatment Expansion but Keeps Prevention Approval - StockTitan
Invivyd, Inc. (NASDAQ:IVVD) Short Interest Up 5.2% in January - Armenian Reporter
Why Invivyd, Inc. (IVVD) Is Soaring This Year So Far - MSN
10 Micro and Small-Cap Firms Drive Year-to-Date Gains - Insider Monkey
Invivyd, Inc. (NASDAQ:IVVD) Sees Significant Growth in Short Interest - MarketBeat
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):